Evidence map›Paper›PMID 34921960›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2022

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

S Horwitz, O A O'Connor, B Pro, L Trümper, S Iyer, R Advani, N L Bartlett, J H Christensen, F Morschhauser, E Domingo-Domenech and 20 more

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 2 pooled it
24.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 2 syntheses or guidelines pooled it, 247 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Impact of a Virtual Multidisciplinary Lymphoma Tumor Board on Clinical Decision-Making.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026
    Article
  14. Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 14 countries.

S HorwitzMemorial Sloan Kettering Cancer Center, New York, USA. Electronic address: horwitzs@mskcc.org.
O A O'ConnorUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, USA.
B ProDivision of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA.
L TrümperUniversitätsmedizin Göttingen, Göttingen, Germany.
S IyerMD Anderson Cancer Center/University of Texas, Houston, USA.
R AdvaniStanford Cancer Center, Blood and Marrow Transplant Program, Stanford, USA.
N L BartlettWashington University School of Medicine, St. Louis, USA.
J H ChristensenOdense University Hospital, Odense, Denmark.
F MorschhauserCHRU de Lille, Lille cedex, Nord-Pas-de-Calais, France.
E Domingo-DomenechInstitut Catala D'oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
G RossiAzienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.
W S KimSungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
T FeldmanJohn Theurer Cancer Center, Hackensack Meridian Health School of Medicine, Hackensack, USA.
T MenneFreeman Hospital, Newcastle upon Tyne, UK.
D BeladaFourth Department of Internal Medicine - Haematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
Á IllésDebreceni Egyetem, Debrecen, Hajdu-Bihar, Hungary.
K TobinaiNational Cancer Center Hospital, Tokyo, Japan.
K TsukasakiSaitama Medical University International Medical Center, Saitama, Japan.
S-P YehChina Medical University Hospital, Taichung, Taiwan.
A ShustovUniversity of Washington Medical Center, Seattle, USA.
A HüttmannUniversitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany.
K J SavageDepartment of Medical Oncology and University of British Columbia, BC Cancer, Vancouver, Canada.
S YuenCalvary Mater Newcastle Hospital, Waratah, Australia.
P L ZinzaniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
H MiaoMillennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
V BunnMillennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
K FentonSeagen Inc., Bothell, USA.
M FanaleSeagen Inc., Bothell, USA.
M PuhlmannSeagen Inc., Bothell, USA.
T IllidgeDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, Manchester, UK.
Seagen (United States) · USAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCalvary Mater Newcastle Hospital · AUCentre Hospitalier Universitaire de Lille · FRCharles University · CZChina Medical University Hospital · TWEssen University Hospital · DEFreeman Hospital · GBHackensack Meridian Health · USInstitut Català d'Oncologia · ESMemorial Sloan Kettering Cancer Center · USMillennium Engineering and Integration (United States) · USNorthwestern University · USOdense University Hospital · DKSaitama International Medical Center · JPSeattle University · USStanford Blood Center · USSungkyunkwan University · KRTakeda (United States) · USThe Christie NHS Foundation Trust · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Communication Skills Intervention to Promote Transition into SurvivorshipR01CA151899 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HORWITZ, STEVEN · 2011 to 2015
$3.0M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA151899
6 · The paper itself

Abstract

backgroundFor patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival versus CHOP for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. PATIENTS AND

methodsECHELON-2 is a double-blind, double-dummy, randomized, placebo-controlled, active-comparator phase III study. We present an exploratory update of the ECHELON-2 study, including an analysis of 5-year PFS per investigator in the intent-to-treat analysis group.

resultsA total of 452 patients were randomized (1 : 1) to six or eight cycles of A+CHP (N = 226) or CHOP (N = 226). At median follow-up of 47.6 months, 5-year PFS rates were 51.4% [95% confidence interval (CI): 42.8% to 59.4%] with A+CHP versus 43.0% (95% CI: 35.8% to 50.0%) with CHOP (hazard ratio = 0.70; 95% CI: 0.53-0.91), and 5-year overall survival (OS) rates were 70.1% (95% CI: 63.3% to 75.9%) with A+CHP versus 61.0% (95% CI: 54.0% to 67.3%) with CHOP (hazard ratio = 0.72; 95% CI: 0.53-0.99). Both PFS and OS were generally consistent across key subgroups. Peripheral neuropathy was resolved or improved in 72% (84/117) of patients in the A+CHP arm and 78% (97/124) in the CHOP arm. Among patients who relapsed and subsequently received brentuximab vedotin, the objective response rate was 59% with brentuximab vedotin retreatment after A+CHP and 50% with subsequent brentuximab vedotin after CHOP.

conclusionsIn this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS versus CHOP, with a manageable safety profile, including continued resolution or improvement of peripheral neuropathy.

Indexed as

Ki-1 AntigenLymphoma, T-Cell, PeripheralAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinHumansVincristineBrentuximab VedotinKi-1 AntigenVincristinebrentuximab vedotinCHOPfrontline treatmentoverall survivalperipheral T-cell lymphomarandomized clinical trial

Identifiers

PMID34921960
PMCPMC9447792
OpenAlexW4200256437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.